GlaxoSmithKline (Spain)-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2019

  1. Budget impact analysis of subcutaneous belimumab in patients with systemic lupus erythematosus in Spain

    ClinicoEconomics and Outcomes Research, Vol. 11, pp. 757-765

2011

  1. Pharmacokinetic/pharmacodynamic evaluation of amoxicillin, amoxicillin/clavulanate and ceftriaxone in the treatment of paediatric acute otitis media in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 29, Núm. 3, pp. 167-173

2009

  1. Impact of acute otitis media pathogen shifts on the clinical efficacy of several antibiotics: A therapeutic outcomes model

    Journal of Chemotherapy, Vol. 21, Núm. 4, pp. 408-413

2008

  1. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313

2007

  1. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model

    Journal of Antimicrobial Chemotherapy, Vol. 60, Núm. 3, pp. 605-612

2005

  1. Evaluation of antimicrobial treatments in children with acute otitis media in Spain: A pharmacokinetic-pharmacodynamic (PK/PD) approach

    Journal of Chemotherapy, Vol. 17, Núm. 6, pp. 628-635

2003

  1. Evaluación psicométrica comparativa de las versiones en español de 6, 17 y 21 ítems de la Escala de valoración de Hamilton para la evaluación de la depresión

    Medicina Clinica, Vol. 120, Núm. 18, pp. 693-700